Low dose naltrexone for fatigue in prostate cancer on hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if a low dose of the drug naltrexone can help reduce fatigue in men with prostate cancer who are currently receiving hormone therapy (ADT). It may offer a new way to manage tiredness during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has come back after initial treatment and have been on hormone therapy (ADT) for at least 3 months.
- If your cancer has spread, you may be on other hormone treatments like abiraterone or enzalutamide.
- You need to be in generally good health, able to perform daily activities (ECOG score less than 3).
- Your kidney, liver, and blood cell counts must be within acceptable ranges as determined by your doctor.
- You must score less than 43 on a fatigue questionnaire (FACIT-F) at screening, meaning you have at least moderate tiredness.
- You cannot have had chemotherapy in the last 3 months or be taking PARP inhibitors or any other experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low dose of naltrexone to treat ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome). It aims to find the best dose that helps symptoms and is safe. If you live in Alabama, are between 18 and 65, and have been diagnosed with ME/CFS using specific medical criteria, you may be able to join.
This trial studies whether a low dose of naltrexone can reduce long-lasting nerve-related pain in adults living with HIV. It may help if your pain has been ongoing and you have stable HIV control.
This trial tests whether a low dose of naltrexone, a medication that may help calm overactive immune and pain signals, can reduce pain and improve daily life in people with complex regional pain syndrome (CRPS), a chronic condition that often causes severe pain and swelling.
This Phase 2 study tests whether low-dose naltrexone can reduce pain from vulvodynia. It also looks at how well it works across different vulvodynia types, comparing to what participants are already doing for symptoms.
This trial tests a natural supplement for fatigue in cancer survivors. You must have had fatigue for at least a month and be otherwise stable.
This Phase 2 trial studies whether a low dose of naltrexone can reduce painful nerve pain caused by diabetes. It may help people whose diabetic nerve pain did not improve with at least one standard treatment.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.